TCL Archive Gynecologic Oncology Group To Conduct Phase III Trial of Xyotax For Ovarian Cancer April 30, 2004
TCL Archive Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study December 26, 2014
TCL Archive Massive New Radiation Research program Costing From $300-$400 Million Over 10 Years Suggested February 11, 1977
TCL Archive Perjeta Neoadjuvant Therapy Granted Accelerated Approval In HER2 Breast Cancer October 25, 2013
